AI assistant
Sending…
Oramed Pharmaceuticals Inc. — Director's Dealing 2017
Jul 5, 2017
6965_dirs_2017-07-05_8a8504cc-d371-4537-8781-d9d340e60c6f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2017-06-30
Reporting Person: Sank Leonard (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-06-30 | Stock Option (right to buy) | $7.77 | A | 16773 | Acquired | 2027-06-30 | Common Stock (16773) | Direct |
Footnotes
F1: The Stock Option will vest in 3 equal installments of 5,591 on each of December 31, 2017, December 31, 2018 and December 31, 2019.
More from Oramed Pharmaceuticals Inc.
Interim / Quarterly Report
2026
May 19
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Capital/Financing Update
2026
Feb 20
Major Shareholding Notification
2026
Feb 9
Director's Dealing
2026
Jan 29
Major Shareholding Notification
2026
Jan 29
Director's Dealing
2026
Jan 29